Vivesto AB (FRA:OMAX)

Germany flag Germany · Delayed Price · Currency is EUR
0.0022
0.00 (0.00%)
At close: Apr 24, 2026
Market Cap8.11M -33.3%
Revenue (ttm)n/a
Net Income-3.15M
EPS-0.01
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open0.0022
Previous Close0.0022
Day's Range0.0022 - 0.0022
52-Week Range0.0014 - 0.0198
Betan/a
RSI47.05
Earnings DateMay 13, 2026

About Vivesto AB

Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known a... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1988
Employees 4
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol OMAX

Financial Performance

Financial numbers in SEK Financial Statements